Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions

Differential Expression of Glut 1 mRNA and Protein Levels Correlates with Increased Sensitivity to the Glyco-Conjugated Nitric Oxide Donor (2-glu-SNAP) in Different Tumor Cell Types

(2014) P.R. Subbarayan et al.   JOURNAL OF CHEMOTHERAPY

A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor

(2011) Kyeong Lee et al.   ARCHIVES OF PHARMACAL RESEARCH

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq

(2011) J. Schodel et al.   BLOOD

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

GSK-3  regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1 

(2011) D. Flugel et al.   BLOOD

Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors

(2011) Y. Lou et al.   CANCER RESEARCH

An activator of PHD2, KRH102140, decreases angiogenesis via inhibition of HIF-1α

(2011) Manoj Nepal et al.   CELL BIOCHEMISTRY AND FUNCTION

HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia

(2011) Thomas Hackenbeck et al.   CELL CYCLE

Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response

(2011) Minna Heikkilä et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Akt signalling in health and disease

(2011) Ingeborg Hers et al.   CELLULAR SIGNALLING

A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies

(2011) J. W. Moroney et al.   CLINICAL CANCER RESEARCH

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

(2011) S. Modi et al.   CLINICAL CANCER RESEARCH

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

(2011) Karen M VanderMolen et al.   JOURNAL OF ANTIBIOTICS

Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis

(2011) Fabio Pacchiano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dynamic contrast-enhanced-MRI of tumor hypoxia

(2011) Tormod A.M. Egeland et al.   MAGNETIC RESONANCE IN MEDICINE

Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?

(2011) Katrien De Bock et al.   Nature Reviews Clinical Oncology

Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

(2011) Jin-Ji Yang et al.   NUCLEAR MEDICINE COMMUNICATIONS

A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

(2011) I. Altomare et al.   ONCOLOGIST

Degradation of HIF-1alpha under Hypoxia Combined with Induction of Hsp90 Polyubiquitination in Cancer Cells by Hypericin: a Unique Cancer Therapy

(2011) Tilda Barliya et al.   PLoS One

CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors

(2011) R. Le Floch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy

(2011) Kavitha Ramasamy Reddy et al.   PROSTATE

Inhibition of tumor lactate oxidation: Consequences for the tumor microenvironment

(2011) Morten Busk et al.   RADIOTHERAPY AND ONCOLOGY

Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck

(2011) Kasper Toustrup et al.   RADIOTHERAPY AND ONCOLOGY

Genetic and Functional Studies Implicate HIF1  as a 14q Kidney Cancer Suppressor Gene

(2011) C. Shen et al.   Cancer Discovery

Thioredoxin and thioredoxin reductase: Current research with special reference to human disease

(2010) Arne Holmgren et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain

(2010) Obinna I. Ndubuizu et al.   BRAIN RESEARCH

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

(2010) Daniel Cejka et al.   CANCER BIOLOGY & THERAPY

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

(2010) Ramesh K. Ramanathan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

(2010) Karen E. Bullock et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

(2010) Justine Yang Bruce et al.   INVESTIGATIONAL NEW DRUGS

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

(2010) Qing Zhou et al.   INVESTIGATIONAL NEW DRUGS

HIF-1 and HIF-2 transcription factors — Similar but not identical

(2010) Agnieszka Loboda et al.   MOLECULES AND CELLS

Avastin's commercial march suffers setback

(2010) Malorye Allison   NATURE BIOTECHNOLOGY

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

(2010) J. Summers et al.   ONCOLOGIST

HIF-2  deletion promotes Kras-driven lung tumor development

(2010) J. Mazumdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer

(2010) Wonsik Choi et al.   RADIOTHERAPY AND ONCOLOGY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors

(2009) Toshio Shimizu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Suppression of Hypoxia-Inducible Factor 2  Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells

(2009) A. M. Roberts et al.   CANCER RESEARCH

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

(2009) A. J. Tevaarwerk et al.   CLINICAL CANCER RESEARCH

Inhibiting the Hypoxia Response for Cancer Therapy: The New Kid on the Block

(2009) M. Y. Koh et al.   CLINICAL CANCER RESEARCH

Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1  Axis

(2009) E. Pencreach et al.   CLINICAL CANCER RESEARCH

17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside

(2009) Saad Usmani et al.   CURRENT MOLECULAR MEDICINE

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab

(2009) Gang Niu et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target

(2009) Piotr J Wysocki   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Genome-wide Association of Hypoxia-inducible Factor (HIF)-1α and HIF-2α DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts

(2009) David R. Mole et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines

(2009) Yun Jung Choi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1  and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia

(2009) J. Yang et al.   MOLECULAR AND CELLULAR BIOLOGY

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

(2009) D. L. Schwartz et al.   MOLECULAR CANCER THERAPEUTICS

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Using YC-1 to overcome the radioresistance of hypoxic cancer cells

(2009) So Young Moon et al.   ORAL ONCOLOGY

Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma

(2009) Kotaro Miyake et al.   PANCREAS

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

(2009) K. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Artificial ligand binding within the HIF2  PAS-B domain of the HIF2 transcription factor

(2009) T. H. Scheuermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

(2009) K. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of hypoxia-inducible factor-1α by NF-κB

(2008) Patrick van Uden et al.   BIOCHEMICAL JOURNAL

Rapid degradation of hypoxia-inducible factor-1α by KRH102053, a new activator of prolyl hydroxylase 2

(2008) H J Choi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH

(2008) J. Chiche et al.   CANCER RESEARCH

Combination Strategy Targeting the Hypoxia Inducible Factor-1  with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

(2008) H. M.W. Verheul et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts

(2008) Esther G. C. Troost et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

PX-478, an inhibitor of hypoxia-inducible factor-1α, enhances radiosensitivity of prostate carcinoma cells

(2008) Sanjeewani T. Palayoor et al.   INTERNATIONAL JOURNAL OF CANCER

Abnormal Sympathoadrenal Development and Systemic Hypotension in PHD3-/- Mice

(2008) T. Bishop et al.   MOLECULAR AND CELLULAR BIOLOGY

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells

(2008) Annick Muhlethaler-Mottet et al.   Molecular Cancer

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 

(2008) M. Y. Koh et al.   MOLECULAR CANCER THERAPEUTICS

A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1 

(2008) S. H. Li et al.   MOLECULAR CANCER THERAPEUTICS

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

(2008) T. E. Wood et al.   MOLECULAR CANCER THERAPEUTICS

A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth

(2008) L. M. Greenberger et al.   MOLECULAR CANCER THERAPEUTICS

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198

(2008) Theresa M. LaVallee et al.   MOLECULAR CANCER THERAPEUTICS

A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines

(2007) A Mukherjee et al.   BRITISH JOURNAL OF PHARMACOLOGY

Comparison of Helzel and OxyLite Systems in the Measurements of Tumor Partial Oxygen Pressure (pO2)

(2007) Bixiu Wen et al.   RADIATION RESEARCH